Evidence map›Paper›PMID 32954021›Full record

ArticleeNeurologicalSci2020

JC virus granule cell neuronopathy associated with Ruxolitinib: A case report and review of the literature.

Kentaro Nakayama, Masataka Nakamura, Akiko Konishi, Satoshi Kaneko, Kazuo Nakamichi, Masayuki Saijo, Yusuke Yakushiji, Hirofumi Kusaka

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in eNeurologicalSci, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. JC Polyomavirus Infection: A Narrative Review.Infectious diseases and therapy · 2025
    Review
  2. Article
  3. Article
  4. Review
  5. Clinical drug therapies and biologicals currently used or in clinical trial to treat COVID-19.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kentaro NakayamaDepartment of Neurology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata, Osaka 5731010, Japan.
Masataka NakamuraDepartment of Neurology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata, Osaka 5731010, Japan.
Akiko KonishiFirst Department of Internal Medicine, Kansai Medical University, 2-5-1, Shinmachi, Hirakata, Osaka 5731010, Japan.
Satoshi KanekoDepartment of Neurology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata, Osaka 5731010, Japan.
Kazuo NakamichiDepartment of Virology 1, National Institute of Infectious Diseases, 1-23-1, Toyama, Shinjuku-ku, Tokyo 1628640, Japan.
Masayuki SaijoDepartment of Virology 1, National Institute of Infectious Diseases, 1-23-1, Toyama, Shinjuku-ku, Tokyo 1628640, Japan.
Yusuke YakushijiDepartment of Neurology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata, Osaka 5731010, Japan.
Hirofumi KusakaDepartment of Neurology, Kansai Medical University, 2-5-1, Shinmachi, Hirakata, Osaka 5731010, Japan.
Kansai Medical University · JPNational Institute of Infectious Diseases · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

•We report here a case of JC virus granule cell neuronopathy associated with Ruxolitinib•It is worthwhile considering the possibility of JCV-GCN in myelofibrosis patients receiving ruxiolitinib, who present with progressive cerebellar symptoms and cerebellar atrophy.•Combination therapy using mefloquine and mirtazapine may be an effective treatment.

Indexed as

Granule cell neuronopthyJC virusMyelofibrosisProgressive multifocal leukoencephalopathyRuxolitinib

Identifiers

PMID32954021
PMCPMC7486434
OpenAlexW3082788820

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.